Cargando…
Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression
BACKGROUND: Immunotherapy targeting programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) has been shown to be effective in a variety of malignancies but has poor efficacy in pancreatic ductal adenocarcinoma (PDAC). Studies have shown that PD-L1 expression in tumors is an important indicato...
Autores principales: | Zheng, Nan-Nan, Zhou, Min, Sun, Fang, Huai, Man-Xiu, Zhang, Yi, Qu, Chun-Ying, Shen, Feng, Xu, Lei-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383845/ https://www.ncbi.nlm.nih.gov/pubmed/32774054 http://dx.doi.org/10.3748/wjg.v26.i26.3737 |
Ejemplares similares
-
Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1
por: Cao, Meng-Tong, et al.
Publicado: (2023) -
Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression
por: Wynn, Daniel T, et al.
Publicado: (2022) -
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019) -
Identification
of a Protein Arginine Methyltransferase
7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor
por: Feoli, Alessandra, et al.
Publicado: (2023) -
Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer
por: Liu, Yi-Zhi, et al.
Publicado: (2020)